Meeting
2019 Genitourinary Cancers Symposium
Is cytoreductive nephrectomy necessary in metastatic renal cell carcinoma with primary kidney tumor in situ treated by sunitinib: Real-world data from a single Chinese center.
Authors
Wen-Hao Xu
Fudan University Shanghai Cancer Center, Shanghai, China
Wen-Hao Xu , Yuan-Yuan Qu , Hong-Kai Wang , Hai-Liang Zhang , Dingwei Ye
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 570)
DOI
10.1200/JCO.2019.37.7_suppl.570
Abstract #
570
Poster Bd #
E9
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world practice patterns, treatment-related toxicity, and survival outcomes in older patients with metastatic renal cell carcinoma: Results from the Canadian Kidney Cancer information system (CKCis).
First Author: Lauren Caitlin Curry
Poster
2024 ASCO Genitourinary Cancers Symposium
Real world evidence from a retrospective multi-center analysis on first-line therapy for metastatic renal cell carcinoma with non-clear cell and/or sarcomatoid histologies.
First Author: Pia Paffenholz
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani